de en
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
    3. Supervisory Board

    Contact

    1. Germany
    2. UK

    Career

    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers

    Information

    1. Events
    2. Information Request
  • Remimazolam

    Sedation & anesthesia market

    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation

    Product Information

    1. About Remimazolam
    2. Clinical trials

    Medical Information

  • Pipeline

    Portfolio

    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA

    Glossary

    1. A_Z
  • Partnering

    Strategy

    1. Partnering strategy

    Licensing projects

    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
  • Media and Investors

    At a glance

    1. General Information
    2. Contact

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board

    Annual general meeting

    2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
  • Scientific Hub
<p><a href="http://bethecatalyst.net/" target="_blank"><span class="big">Be the catalyst</span><span class="small">Visit our new Scientific Hub here</span></a></p>

Be the catalystVisit our new Scientific Hub here

prev next
  • Media and Investors  » 
  • Newsroom  » 
  • Press Releases  » 
  • 2010
  • 12/06/2010

     PAION reports positive preclinical results of its substance Solulin in the indication haemophilia

    • PDF

  • 11/22/2010

    PAION reports positive results of its short acting anaesthetic/sedative Remimazolam (CNS 7056) in a Phase IIb study

    • PDF

  • 11/10/2010

    PAION AG reports results for the first nine months 2010

    • PDF

  • 10/15/2010

    PAION expands Desmoteplase agreement with Lundbeck

    • PDF

  • 09/27/2010

    PAION completes Phase IIb study with short-acting anesthetic/sedative Remimazolam (CNS 7056)

    • PDF

  • 08/11/2010

    PAION AG reports results for the first half-year 2010

    • PDF

  • 08/02/2010

    PAION's Phase IIb study with its anaesthetic/sedative Remimazolam (CNS 7056) ahead of schedule

    • PDF

  • 05/28/2010

    PAION starts Phase IIb study with its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy

    • PDF

  • 05/11/2010

    PAION AG reports results for the first quarter 2010

    • PDF

  • 05/10/2010

    PAION AG enters into an equity facility agreement for EUR 15 million

    • PDF

  • 05/10/2010

    Start of Japanese Phase I with CNS 7056 triggered first milestone of one million USD for PAION from Ono Pharmaceutical

    • PDF

  • 04/27/2010

    PAION reaches agreement with FDA on Phase IIb study design for its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy

    • PDF

  • 04/21/2010

    Filing of IND application for GGF2 in heart failure by PAION's partner Acorda Therapeutics triggers first milestone payments

    • PDF

  • 03/16/2010

    PAION's partner Lundbeck initiates Japanese Clinical Phase II Trial with Desmoteplase in ischaemic stroke

    • PDF

  • 03/16/2010

    PAION AG reports results for the fiscal year 2009

    • PDF

  • 02/25/2010

    PAION's partner Lundbeck presented data from a post-hoc analysis using Desmoteplase in ischaemic stroke

    • PDF

  • 02/04/2010

    PAION announces initiation of clinical development activities with short-acting anaesthetic/sedative CNS 7056 (ONO's Development code: ONO-2745) by its Partner ONO Pharmaceutical in Japan

    • PDF

  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Heussstraße 25 | 52078 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
    3. Supervisory Board
  2. Contact +
    1. Germany
    2. UK
  3. Career +
    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers
  4. Information +
    1. Events
    2. Information Request
Remimazolam
  1. Sedation & anesthesia market +
    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation
  2. Product Information +
    1. About Remimazolam
    2. Clinical trials
  3. Medical Information
Pipeline
  1. Portfolio +
    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA
  2. Glossary +
    1. A_Z
Partnering
  1. Strategy +
    1. Partnering strategy
  2. Licensing projects +
    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
Media and Investors
  1. At a glance +
    1. General Information
    2. Contact
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
  6. Annual general meeting +
    1. 2021
    2. 2020
    3. 2019
    4. 2018
    5. 2017
    6. 2016
    7. 2015
    8. 2014
    9. 2013
    10. 2012
    11. 2011
    12. 2010
Scientific Hub
Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

Accept all Save
Privacy Statement Imprint